Pattern of interleukin‐1β secretion in response to lipopolysaccharide and ATP before and after interleukin‐1 blockade in patients with CIAS1 mutations
Open Access
- 30 August 2007
- journal article
- autoinflmmatory disease
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (9), 3138-3148
- https://doi.org/10.1002/art.22842
Abstract
Objective To examine the synthesis, processing, and secretion of interleukin-1β (IL-1β), as well as the clinical and biologic effects of IL-1 blockade, in patients with chronic infantile neurologic, cutaneous, articular (CINCA) syndrome and Muckle-Wells syndrome (MWS), in an effort to understand the molecular mechanisms linking mutations of the CIAS1 gene and IL-1β hypersecretion, and the underlying response to IL-1 receptor antagonist (IL-1Ra). Methods Six patients with CINCA syndrome or MWS were treated with IL-1Ra and followed up longitudinally. Monocytes obtained from the patients and from 24 healthy donors were activated with lipopolysaccharide (LPS) for 3 hours, and intracellular and secreted IL-1β levels were determined by Western blotting and enzyme-linked immunosorbent assay before and after exposure to exogenous ATP. Results LPS-induced IL-1β secretion was markedly increased in monocytes from patients with CIAS1 mutations. However, unlike in healthy subjects, secretion of IL-1β was not induced by exogenous ATP. Treatment with IL-1Ra resulted in a dramatic clinical improvement, which was paralleled by an early and strong down-regulation of LPS-induced IL-1β secretion by the patients' cells in vitro. Conclusion Our results showed that the requirements of ATP stimulation for IL-1β release observed in healthy individuals are bypassed in patients bearing CIAS1 mutations. This indicates that cryopyrin is the direct target of ATP and that the mutations release the protein from the requirement of ATP for activation. In addition, the dramatic amelioration induced by IL-1Ra treatment is at least partly due to the strong decrease in IL-1β secretion that follows the first injections of the antagonist. These findings may have implications for other chronic inflammatory conditions characterized by increased IL-1β.Keywords
This publication has 39 references indexed in Scilit:
- Histone deacetylase inhibitors prevent exocytosis of interleukin-1β-containing secretory lysosomes: role of microtubulesBlood, 2006
- Clinical and genetic characterization of Italian patients affected by CINCA syndromeRheumatology, 2006
- Cryopyrin activates the inflammasome in response to toxins and ATPNature, 2006
- Enhanced interleukin‐1β and interleukin‐18 release in a patient with chronic infantile neurologic, cutaneous, articular syndromeArthritis & Rheumatism, 2004
- Inflammatory CaspasesCell, 2004
- Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic feverJournal of Allergy and Clinical Immunology, 2001
- A Glu-496 to Ala Polymorphism Leads to Loss of Function of the Human P2X7 ReceptorJournal of Biological Chemistry, 2001
- Altered Cytokine Production in Mice Lacking P2X7ReceptorsJournal of Biological Chemistry, 2001
- Interleukin-1, Interleukin-1 Receptors and Interleukin-1 Receptor AntagonistInternational Reviews of Immunology, 1998
- Arthropathy with rash, chronic meningitis, eye lesions, and mental retardationThe Journal of Pediatrics, 1981